Codiak Biosciences Inc. (CDAK) PT Raised to 'Street High' $31 at Wedbush Following Data

December 30, 2020 12:15 PM EST
Get Alerts CDAK Hot Sheet
Price: $17.20 -8.75%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten raised the price target on Codiak Biosciences Inc. (NASDAQ: CDAK) to a 'Street High' $31.00 (from $19.00) while maintaining an Outperform rating.

The analyst notes - "initial Ph 1 data with CDAK’s exoIL-12 program in healthy volunteers showed no treatment-related adverse events and importantly, no systemic IL-12 exposure through 10 days of follow-up."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change